Ato
Acute Promyelocytic Leukemia (APL)
The Affiliated People's Hospital of Ningbo UniversityPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Acute Promyelocytic Leukemia (APL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
QTX-2101 Quetzal Therapeutics | Phase 3 | B |
Apg-2575 The Affiliated People's Hospital of Ningbo University | Phase 2/3 | B |
Ruxolitinib The Affiliated People's Hospital of Ningbo University | Phase 2/3 | B |
MARBLE DUST SDK Therapeutics, Inc. | Phase 1 | CC |
Same molecule, other indications
Ato is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →